Trinity Biotech (Trinity Biotech) EBIT per Share : $-3.70 (TTM As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech EBIT per Share?

Trinity Biotech's EBIT per Share for the three months ended in Sep. 2023 was $-0.54. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.70.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Trinity Biotech's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Trinity Biotech was 208.10% per year. The lowest was -71.10% per year. And the median was -3.10% per year.

TRIB's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.55
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Trinity Biotech's EBIT for the three months ended in Sep. 2023 was $-4.11 Mil.

Trinity Biotech EBIT per Share Historical Data

The historical data trend for Trinity Biotech's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech EBIT per Share Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-3.50

-4.60

-0.26

1.49

-2.45

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-1.02	-0.74	-0.49	-1.93	-0.54

Trinity Biotech EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Trinity Biotech's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-16.524	/	6.747
=	-2.45

Trinity Biotech's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.111	/	7.666
=	-0.54

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.70

Trinity Biotech (NAS:TRIB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Trinity Biotech EBIT per Share Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.